bf/NASDAQ:IOVA_icon.jpeg

NASDAQ:IOVA

Iovance Biotherapeutics, Inc.

  • Stock

USD

Last Close

2.31

06/11 22:32

Market Cap

2.18B

Beta: 0.20

Volume Today

10.67M

Avg: 3.51M

PE Ratio

−4.56

PFCF: −7.39

    Description

    Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, ...Show More

    Earnings

    Earnings per Share (Estimate*)

    -0.8-0.6-0.4-0.22019-11-042020-12-302022-05-052023-11-072024-11-07

    Revenue (Estimate*)

    20M40M60M80M2019-11-042020-12-302022-05-052023-11-072024-11-07

    *Estimate based on analyst consensus